The EC Pharmaceutical Report Kent Bernard, Nov 12, 2008 The 2008 EC Sector Inquiry Regarding Pharmaceuticals: What Does It Mean from a Research-Based Company Perspective? A sector inquiry is never…

This article is part of a Chronicle. See more from this Chronicle David Balto, Nov 12, 2008 The Federal Trade Commission’s (“FTC”) powers under Section 5 of the FTC Act…

This article is part of a Chronicle. See more from this Chronicle Thomas Cueni, Nov 12, 2008 While the pharmaceutical sector waits for the European Commission’s interim report and hearing…

This article is part of a Chronicle. See more from this Chronicle Suzanne Innes-Stubb, Mark Powell, Nov 12, 2008 The European Commission and the U.K. Competition Commission (“CC”) both have…

This article is part of a Chronicle. See more from this Chronicle Sean-Paul Brankin, Nov 12, 2008 One reaction to the pharmaceuticals sector inquiry, particularly from the originator side of…

This article is part of a Chronicle. See more from this Chronicle David Hull, Nov 12, 2008 Efforts by innovative pharmaceutical companies to protect their markets against generic drugs have…

This article is part of a Chronicle. See more from this Chronicle Kent Bernard, Nov 12, 2008 A sector inquiry is never pleasant for the sector involved. It is much…

This article is part of a Chronicle. See more from this Chronicle Joe Sims, Nov 12, 2008 As this is published, the United States has just elected a new President.…

This article is part of a Chronicle. See more from this Chronicle Nov 12, 2008 The basic question I am addressing concerns the wisdom of using the “unfair method of…